Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The aim of the present study was to evaluate the per-lesion sensitivity and specificity of the Korean Liver Cancer Association–National Cancer Center (KLCA-NCC) 2022 criteria for the noninvasive diagnosis of hepatocellular carcinoma (HCC), with intraindividual comparison of the diagnostic performance of magnetic resonance imaging with extracellular agents (ECA-MRI) and hepatobiliary agents (HBA-MRI). Materials and Methods Patients at high risk for HCC who were referred to a tertiary academic institution for hepatic lesions with size ≥ 10 mm between July 2019 and June 2022 were enrolled. A total of 91 patients (mean age, 58.1 years; 76 men and 15 women) with 118 lesions who underwent both ECA-MRI and HBA-MRI were eligible for final analysis. The per-lesion sensitivities and specificities of the KLCA-NCC 2022 criteria using ECA-MRI and HBA-MRI were compared using McNemar’s test. Results The 118 lesions were 93 HCCs, 4 non-HCC malignancies, and 21 benign lesions. On HBA-MRI, the “definite” HCC category showed significantly higher sensitivity than ECA-MRI (78.5% vs. 58.1%, p < 0.001), with identical specificity (92.0% vs. 92.0%, p > 0.999). For “probable” or “definite” HCC categories, there were no differences in the sensitivity (84.9% vs. 84.9%, p > 0.999) and specificity (84.0% vs. 84.0%, p > 0.999) between ECA-MRI and HBA-MRI. Conclusion The “definite” HCC category of the KLCA-NCC 2022 criteria showed higher sensitivity in diagnosing HCC on HBA-MRI compared with ECA-MRI, without compromising specificity. There were no significant differences in the sensitivity and specificity of “probable” or “definite” HCC categories according to ECA-MRI and HBA-MRI.
Abstract
Purpose The aim of the present study was to evaluate the per-lesion sensitivity and specificity of the Korean Liver Cancer Association–National Cancer Center (KLCA-NCC) 2022 criteria for the noninvasive diagnosis of hepatocellular carcinoma (HCC), with intraindividual comparison of the diagnostic performance of magnetic resonance imaging with extracellular agents (ECA-MRI) and hepatobiliary agents (HBA-MRI). Materials and Methods Patients at high risk for HCC who were referred to a tertiary academic institution for hepatic lesions with size ≥ 10 mm between July 2019 and June 2022 were enrolled. A total of 91 patients (mean age, 58.1 years; 76 men and 15 women) with 118 lesions who underwent both ECA-MRI and HBA-MRI were eligible for final analysis. The per-lesion sensitivities and specificities of the KLCA-NCC 2022 criteria using ECA-MRI and HBA-MRI were compared using McNemar’s test. Results The 118 lesions were 93 HCCs, 4 non-HCC malignancies, and 21 benign lesions. On HBA-MRI, the “definite” HCC category showed significantly higher sensitivity than ECA-MRI (78.5% vs. 58.1%, p < 0.001), with identical specificity (92.0% vs. 92.0%, p > 0.999). For “probable” or “definite” HCC categories, there were no differences in the sensitivity (84.9% vs. 84.9%, p > 0.999) and specificity (84.0% vs. 84.0%, p > 0.999) between ECA-MRI and HBA-MRI. Conclusion The “definite” HCC category of the KLCA-NCC 2022 criteria showed higher sensitivity in diagnosing HCC on HBA-MRI compared with ECA-MRI, without compromising specificity. There were no significant differences in the sensitivity and specificity of “probable” or “definite” HCC categories according to ECA-MRI and HBA-MRI.
참고문헌 (22)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Clin Liver Dis, 13, pp.1~ (2019)
- Asrani SK, "Burden of liver diseases in the world", J Hepatol, 70, pp.151~171 (2019)
- Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- "Liver Imaging Reporting and Data System (LI-RADS) version 2018 Core" (2018)[URL]
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 20(7), pp.1042~1113 (2019), 대한영상의학회[DOI]
- Tae-Hyung Kim, "Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update", Clinical and Molecular Hepatology, 25(3), pp.245~263 (2019), 대한간학회
- Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
- Kim TK, "Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small(1-2-cm)hepatic nodules in patients at high risk for hepatocellular carcinoma", Radiology, 259, pp.730~738 (2011)
- Tang A, "Evidence supporting LI-RADS major features for CT-and MR imaging-based diagnosis of hepatocellular carcinoma : a systematic review", Radiology, 286, pp.29~48 (2018)
- Cohen J, "A coefficient of agreement for nominal scales", Educ Psychol Meas, 20, pp.37~46 (1960)
- Byun J, "Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3. 0 cm on gadoxetate disodium-enhanced MRI", Hepatol Int, 14, pp.534~543 (2020)
- Jeon SK, "Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates", Eur Radiol, 30, pp.4762~4771 (2020)
- 이선영, "Validation of the Korean Liver Cancer Association-National Cancer Center 2018 Criteria for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using Magnetic Resonance Imaging", Journal of Liver Cancer, 20(2), pp.120~127 (2020), 대한간암학회[DOI]
- 이선영, "Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging", Clinical and Molecular Hepatology, 26(3), pp.340~351 (2020), 대한간학회[DOI]
- Kim DH, "Diagnostic performance of KLCA-NCC 2018 criteria for hepatocellular carcinoma using magnetic resonance imaging : a systematic review and meta-analysis", Diagnostics(Basel), 11, pp.1763~ (2021)
- Hwang SH, "Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging", Eur Radiol, 31, pp.4492~4503 (2021)
- Park SH, "Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients", Eur Radiol, 31, pp.4751~4763 (2021)
- 이상민, "Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018", Korean Journal of Radiology, 22(7), pp.1066~1076 (2021), 대한영상의학회[DOI]
- Joo I, "Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI : can hypointensity on the hepatobiliary phase be used as an alternative to washout?", Eur Radiol, 25, pp.2859~2868 (2015)
- Choi MH, "MRI of small hepatocellular carcinoma : typical features are less frequent below a size cutoff of 1. 5 cm", AJR Am J Roentgenol, 208, pp.544~551 (2017)
- Yoon J, "Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis", Liver Int, 41, pp.1641~1651 (2021)